Business Context and Reporting Period
This Form 6-K filing by Compugen Ltd. covers the month of December 2012, specifically reporting on a corporate transaction dated December 27, 2012. The filing details a second amendment to a funding agreement with Baize Investments (Israel) Ltd. regarding research funding for therapeutic monoclonal antibody (mAb) product candidates in the oncology field.
Key Financial Metrics
The filing does not provide standard financial statements, revenue, profit, cash flow, or margin data. The primary financial details relate to the amended funding agreement:
- Original Investment Amount: $8,000,000.
- Amended Investment Options: Baize may pay either $5,000,000 or $7,500,000 by April 30, 2013.
- Total Potential Investment: The total Investment Amount will be either $8,000,000 or $10,500,000 depending on the final payment.
- Contingent Payment: If the final payment is not made by April 30, 2013, Baize is entitled to a cumulative maximum of $1,500,000 on or after May 1, 2013.
Material Changes Versus Prior Period
The amendment introduces several material changes to the original agreement dated December 20, 2011, and amended on July 24, 2012:
- Target Reduction: The number of specified oncology targets included in the arrangement was reduced from eight (8) to six (6).
- Payment Deadline Extension: The deadline for the final payment was extended from December 31, 2012, to April 30, 2013.
- Share Exchange Window: The period during which Baize can exchange its Participation Interest for ordinary shares was extended from January 1, 2014, through March 31, 2014, to January 1, 2015, through March 31, 2015.
- Share Calculation Method: The fixed share count of 1,454,545 was replaced with a formula based on the Net Baize Investment divided by the average closing price of shares over the 20 trading days prior to election.
- Cash Alternative: If the average closing price is less than $5.50 per share, Compugen has the right to pay cash in lieu of shares.
- Termination Consequences: If the final payment is missed, Baize will no longer receive Compugen shares (previously 500,000 shares were due under the prior terms).
Guidance, Outlook, and Risks
The filing does not contain forward-looking financial guidance or management commentary on general business outlook. Key risks and contingencies identified include:
- Funding Contingency: The total investment and the number of targets covered depend on Baize's election to pay $5,000,000 or $7,500,000 by the April 30, 2013 deadline.
- Termination Risk: Failure to make the final payment by April 30, 2013, grants Compugen the right to terminate the agreement, limiting Baize's return to a maximum of $1,500,000 and forfeiting any equity participation.
- Market Price Risk: The number of shares Baize receives upon exchange is variable and dependent on the company's stock price, with a floor price of $5.50 triggering a potential cash settlement.
Important Facts for Investor Verification
- Verify whether Baize Investments has elected to pay $5,000,000 or $7,500,000 by the April 30, 2013 deadline.
- Confirm the current status of the six (or potentially eight) oncology targets included in the funding agreement.
- Monitor the company's stock price relative to the $5.50 threshold to assess the likelihood of a cash settlement versus share issuance upon Baize's election.
- Review the impact of the extended payment timeline on the company's immediate liquidity needs.